- In March 2025, Eli Lilly has introduced its diabetes and weight-loss drug, Mounjaro, in India, marking a significant step in addressing the country's obesity and type 2 diabetes challenges. This move is expected to intensify competition among pharmaceutical companies in the Indian market.
- In April 2025, Novo Nordisk has launched its obesity drug, Wegovy, in Thailand, its first entry into the Southeast Asian market. This expansion is part of the company's strategy to meet the rising demand for obesity treatments in the region.
